A simple measure of waist circumference could identify chronic heart failure patients who would benefit most from mineralocorticoid receptor antagonists, according to a review published July 25 in JAMA Cardiology.
In following patients with heart failure for up to 15 years, Spanish cardiologists found left ventricular ejection fraction (LVEF) followed an inverse U-shape: LVEF improved for the first year, then plateaued for the rest of the first decade and declined in the following years—especially before death.
Rapid Medical has received CE mark approval for its Tigertriever 13 clot retriever, the smallest such device on the market which is designed to treat intracranial vessels between one and 2.5 millimeters.
Italian physicians reported what they believe to be “unprecedented clinical improvement” from interleukin-1 suppression in a patient with dilated cardiomyopathy.
A former jail nurse has been sentenced to 15 years in prison for manslaughter after she was found guilty of causing the death of a diabetic inmate who went a week without insulin.
A panel of experts believes genetic testing of individuals at risk of familial hypercholesterolemia (FH) could “alter the natural history” of the condition, which is estimated to be undiagnosed in more than 27 million people worldwide, including more than 1 million in the United States.
DUBLIN — July 31, 2018 — Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for the Implantable System for Remodulin® (ISR) to treat patients with pulmonary arterial hypertension (PAH).
A group of researchers from a Veterans Affairs health system in California shared their experience with limited left ventricular echocardiography, something they believe could reduce the cost and time required for testing in select patients.
Higher body mass index (BMI) as a young adult may result in higher blood pressure (BP) and left ventricle mass index, resulting in changes to the heart structure, researchers report in the American Heart Association’s (AHA) journal Circulation.
The FDA approved the FreeStyle Libre flash glucose monitoring system, which works for up to 14 days at a time, according to an announcement from device maker Abbott.
